News

New US contracts cool conflict
Enlarge image

BusinessDenmark

New US contracts cool conflict

15.11.2012 - Despite an ongoing dispute, the US government has signed two new contracts with Danish vaccine developer Bavarian Nordic.

The Danish drugmaker announced the closing of two new contracts with the U.S. Department of Homeland Security (DHS) and the National Institutes of Health (NIH). The contracts were valued at up to US$18.9m for the development of recombinant Modified Vaccinia virus Ankara (MVA) vaccines.

The NIH contract, valued at up to US$17.9m, supports the advanced development of an MVA-based human vaccine against the viral haemorrhagic fever Marburg. The DHS contract, valued at nearly US$1m, supports the development of an MVA-based animal vaccine against Foot-and-mouth disease. "These new contracts demonstrate the versatility of our MVA platform for infectious disease vaccines and cancer immunotherapeutics," said Anders Hedegaard, President and CEO of Bavarian Nordic A/S.

Bavarian Nordic is currently in an argument with the US government. Denmark's biggest drugmaker accuses its customer not to fulfil the conditions of a 2007 contract worth US$500m. The government had promised to order 20 million doses of a smallpox vaccine that has less side effects than common ones. As Bloomberg noted, the biotech company had said in August that it would have to shed hundreds of jobs and shut down a plant if the U.S. government didn't order more of the vaccine until January.

© eurobiotechnews.eu/pd

http://www.european-biotechnology-news.com/news/news/2012-04/new-us-contracts-cool-conflict.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • THERAMETRICS (CH)0.05 CHF66.7%
  • PROTHENA PLC (IE)51.61 USD52.6%
  • FLAMEL TECHNOLOGIES (F)12.71 USD34.6%

FLOP

  • MOLOGEN (D)1.80 EUR-28.9%
  • EVOCUTIS (UK)0.04 GBP-20.0%
  • SAREUM HOLDINGS (UK)0.60 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1893.6%
  • NICOX (F)11.17 EUR469.9%
  • SAREUM HOLDINGS (UK)0.60 GBP160.9%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.7%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 26.07.2016